| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10039136 | HBV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS30073496 | HIV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS30073497 | HIV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20011278 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029983 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029984 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029985 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029986 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029987 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20064469 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR2C |
|---|---|
| DrugBank ID | DB00334 |
| Drug Name | Olanzapine |
| Target ID | BE0000533 |
| UniProt ID | P28335 |
| Regulation Type | antagonist |
| PubMed IDs | 11752352; 16336943; 17624999; 16983399; 16918396; 16952163; 10227113; 25032030 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006 Feb 14;71(4):521-9. Epub 2005 Dec 5.@@Overstreet DH, Knapp DJ, Breese GR: Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res. 2007 Sep;31(9):1473-81. Epub 2007 Jul 11.@@Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J: No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. Epub 2006 Sep 19.@@Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52.@@Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52.@@Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22.@@Brafford MV, Glode A: Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. |
| Groups | Approved; Investigational |
| Direct Classification | Benzodiazepines |
| SMILES | CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 |
| Pathways | |
| PharmGKB | PA450688 |
| ChEMBL | CHEMBL715 |
